GleamWall
中文EN

SYBX SYNLOGIC, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1527599 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-99.8%
TTM net income YoY59.2%
TTM EPS YoY79.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-511,875.0%
Net margin-291,987.5%
FCF margin-395,900.0%
EBITDA margin-507,537.5%

Returns

ROE-102.6%
ROA-49.0%
ROIC (approx.)-2,394.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets35.7%
Debt / equity0.00x
Current ratio2.80x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio17.4%
Payout ratio—
Capex / revenue175.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense——$49,000———$22,000—
SG&A expense$695,000$828,000$1.06M$1.03M$818,000$800,000$836,000$1.40M
Operating income-$2.30M-$1.01M-$1.32M-$1.34M-$991,000-$777,000-$898,000-$1.78M
Interest expense———————$0
Pretax income———$1.51M-$2.30M-$529,000—-$714,000
Income tax———$0$0$0—$0
Net income-$3.87M-$543,000$681,000$1.51M-$2.30M-$529,000$317,000-$714,000
EBITDA———-$1.34M-$991,000-$777,000-$898,000-$1.78M
EPS (basic)-0.31-0.040.05—-0.19-0.040.03—
EPS (diluted)-0.31-0.040.05—-0.19-0.040.03—
Weighted avg. shares (diluted)12.42M12.42M12.40M—12.32M12.32M12.39M—
Balance sheet
Cash & equivalents$11.56M$13.18M$14.11M$14.67M$15.59M$17.03M$17.27M$18.86M
Short-term investments———————$0
Current assets$11.80M$13.43M$14.56M$15.40M$16.50M$17.32M$17.92M$19.78M
PP&E, net———————$0
Total assets$11.85M$13.48M$14.61M$15.45M$16.55M$17.37M$17.97M$19.83M
Current liabilities$1.67M$1.46M$2.06M$3.58M$6.23M$4.78M$4.87M$7.08M
Total liabilities$1.67M$1.46M$2.06M$3.58M$6.23M$4.78M$4.87M$7.08M
Shareholders' equity$10.18M$12.02M$12.55M$11.86M$10.32M$12.59M$13.09M$12.75M
Shares outstanding12.25M11.70M11.70M11.70M11.70M11.70M11.70M11.70M
Cash flow statement
Operating cash flow-$1.62M-$922,000-$563,000-$923,000-$1.44M-$399,000-$1.60M-$568,000
Capital expenditure———$0$0$0$0$0
Free cash flow———-$923,000-$1.44M-$399,000-$1.60M-$568,000
Investing cash flow$0$0$0$0$0$155,000$12,000$30,000
Financing cash flow———$0$0$0$0$9,000
Depreciation & amortization———$0$0$0$0$0
Stock-based compensation$5,000$6,000$10,000$30,000$33,000$29,000$25,000$348,000

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.